The U.S. Food and Drug Administration (FDA) Approves Pirtobrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) October 2, 2026 – On October 2, 2026, the U.S. Food and Drug Administration (FDA) announced it approved pirtobrutinib (Jaypirca, Eli Lilly and Company)…
The U.S. Food and Drug Administration (FDA) Approves Sonrotoclax for Mantle Cell Lymphoma May 13, 2026 – On May 13, 2026, the U.S. Food and Drug Administration (FDA) announced it has approved sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2…
The U.S. Food and Drug Administration (FDA) Approves Nivolumab for Hodgkin Lymphoma March 20, 2026- On March 20, 2026, the U.S. Food and Drug Administration (FDA) announced it has approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and…
The U.S. Food and Drug Administration (FDA) Approves Acalabrutinib with Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) February 20, 2025 – On February 20, 2025, the U.S. Food and Drug Administration (FDA) announced it has approved acalabrutinib (Calquence, AstraZeneca)…
The U.S. Food and Drug Administration (FDA) Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma December 5, 2025 – On December 5, 2025, the U.S. Food and Drug Administration (FDA) announced it has approved lisocabtagene maraleucel (Breyanzi, Juno…
The U.S. Food and Drug Administration (FDA) Approves Pirtobrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma December 3, 2025 – On December 3, 2025, the U.S. Food and Drug Administration (FDA) announced it has approved pirtobrutinib (Jaypirca, Eli…
The U.S. Food and Drug Administration (FDA) Approves Epcoritamab-bysp for Follicular Lymphoma Indications November 18, 2025 – On November 18, 2025, the U.S. Food and Drug Administration (FDA) announced it has approved epcoritamab-bysp (Epkinly, Genmab US, Inc.) with lenalidomide and…
On June 18, 2025, the U.S. Food and Drug Administration (FDA) announced it has granted accelerated approval of tafasitamab-cxix (Monjuvi, Incyte Corporation) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL). Tafasitamab-cxix is a monoclonal antibody. Monoclonal…
The U.S. Food and Drug Administration (FDA) Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory Large B-cell Lymphoma February 12, 2025 – On February 12, 2025, the U.S. Food and Drug Administration (FDA) announced it has approved…
The U.S. Food and Drug Administration (FDA) Approves Acalabrutinib (CALQUENCE) for Mantle Cell Lymphoma January 16, 2025 – On January 16, 2025, the U.S. Food and Drug Administration (FDA) announced it has approved acalabrutinib (CALQUENCE, AstraZeneca) with bendamustine and rituximab…
